Literature DB >> 30059292

Ultrasound Measurement of Vascular Density to Evaluate Response to Anti-Angiogenic Therapy in Renal Cell Carcinoma.

Juan D Rojas, Virginie Papadopoulou, Tomasz J Czernuszewicz, Rajalekha M Rajamahendiran, Anna Chytil, Yun-Chen Chiang, Diana C Chong, Victoria L Bautch, W Kimryn Rathmell, Stephen Aylward, Ryan C Gessner, Paul A Dayton.   

Abstract

BACKGROUND: Functional and molecular changes often precede gross anatomical changes, so early assessment of a tumor's functional and molecular response to therapy can help reduce a patient's exposure to the side effects of ineffective chemotherapeutics or other treatment strategies.
OBJECTIVE: Our intent was to test the hypothesis that an ultrasound microvascular imaging approach might provide indications of response to therapy prior to assessment of tumor size.
METHODS: Mice bearing clear-cell renal cell carcinoma xenograft tumors were treated with antiangiogenic and Notch inhibition therapies. An ultrasound measurement of microvascular density was used to serially track the tumor response to therapy.
RESULTS: Data indicated that ultrasound-derived microvascular density can indicate response to therapy a week prior to changes in tumor volume and is strongly correlated with physiological characteristics of the tumors as measured by histology ([Formula: see text]). Furthermore, data demonstrated that ultrasound measurements of vascular density can determine response to therapy and classify between-treatment groups with high sensitivity and specificity. CONCLUSION/SIGNIFICANCE: Results suggests that future applications utilizing ultrasound imaging to monitor tumor response to therapy may be able to provide earlier insight into tumor behavior from metrics of microvascular density rather than anatomical tumor size measurements.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30059292      PMCID: PMC6691901          DOI: 10.1109/TBME.2018.2860932

Source DB:  PubMed          Journal:  IEEE Trans Biomed Eng        ISSN: 0018-9294            Impact factor:   4.538


  61 in total

Review 1.  Molecular pathways in renal cell carcinoma--rationale for targeted treatment.

Authors:  William Y Kim; William G Kaelin
Journal:  Semin Oncol       Date:  2006-10       Impact factor: 4.929

2.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; M Dror Michaelson; Bruce G Redman; Gary R Hudes; George Wilding; Robert A Figlin; Michelle S Ginsberg; Sindy T Kim; Charles M Baum; Samuel E DePrimo; Jim Z Li; Carlo L Bello; Charles P Theuer; Daniel J George; Brian I Rini
Journal:  J Clin Oncol       Date:  2005-12-05       Impact factor: 44.544

3.  Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis.

Authors:  Irene Noguera-Troise; Christopher Daly; Nicholas J Papadopoulos; Sandra Coetzee; Pat Boland; Nicholas W Gale; Hsin Chieh Lin; George D Yancopoulos; Gavin Thurston
Journal:  Nature       Date:  2006-12-21       Impact factor: 49.962

4.  To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.

Authors:  Michele Lamuraglia; Bernard Escudier; Linda Chami; Brian Schwartz; Jérome Leclère; Alain Roche; Nathalie Lassau
Journal:  Eur J Cancer       Date:  2006-09-11       Impact factor: 9.162

5.  Targeting mucosal addressin cellular adhesion molecule (MAdCAM)-1 to noninvasively image experimental Crohn's disease.

Authors:  Christopher Bachmann; Alexander L Klibanov; Timothy S Olson; Jason R Sonnenschein; Jesus Rivera-Nieves; Fabio Cominelli; Klaus F Ley; Jonathan R Lindner; Theresa T Pizarro
Journal:  Gastroenterology       Date:  2006-01       Impact factor: 22.682

6.  [New guidelines to evaluate the response to treatment in solid tumors].

Authors:  F Duffaud; P Therasse
Journal:  Bull Cancer       Date:  2000-12       Impact factor: 1.276

7.  Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.

Authors:  Bruno Morgan; Anne L Thomas; Joachim Drevs; Juergen Hennig; Martin Buchert; Asvina Jivan; Mark A Horsfield; Klaus Mross; Howard A Ball; Lucy Lee; William Mietlowski; Stefan Fuxuis; Clemens Unger; Ken O'Byrne; Andrew Henry; Graham R Cherryman; Dirk Laurent; Margaret Dugan; Dieter Marmé; William P Steward
Journal:  J Clin Oncol       Date:  2003-09-29       Impact factor: 44.544

8.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Authors:  James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

9.  Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment.

Authors:  Hinrich A Wieder; Björn L D M Brücher; Frank Zimmermann; Karen Becker; Florian Lordick; Ambros Beer; Markus Schwaiger; Ulrich Fink; Jörg Rüdiger Siewert; Hubert J Stein; Wolfgang A Weber
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

10.  18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).

Authors:  S Stroobants; J Goeminne; M Seegers; S Dimitrijevic; P Dupont; J Nuyts; M Martens; B van den Borne; P Cole; R Sciot; H Dumez; S Silberman; L Mortelmans; A van Oosterom
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

View more
  9 in total

1.  Quantification of Morphological Features in Non-Contrast-Enhanced Ultrasound Microvasculature Imaging.

Authors:  Siavash Ghavami; Mahdi Bayat; Mostafa Fatemi; Azra Alizad
Journal:  IEEE Access       Date:  2020-01-21       Impact factor: 3.367

Review 2.  Visualization of Microvascular Angiogenesis Using Dual-Frequency Contrast-Enhanced Acoustic Angiography: A Review.

Authors:  Isabel G Newsome; Paul A Dayton
Journal:  Ultrasound Med Biol       Date:  2020-07-20       Impact factor: 2.998

3.  Acoustic Angiography: Superharmonic Contrast-Enhanced Ultrasound Imaging for Noninvasive Visualization of Microvasculature.

Authors:  Isabel G Newsome; Paul A Dayton
Journal:  Methods Mol Biol       Date:  2022

4.  Use of 3-D Contrast-Enhanced Ultrasound to Evaluate Tumor Microvasculature After Nanoparticle-Mediated Modulation.

Authors:  Jihun Kwon; Rajalekha M Rajamahendiran; Needa A Virani; Sijumon Kunjachan; Erin Snay; Max Harlacher; Marios Myronakis; Shinichi Shimizu; Hiroki Shirato; Tomasz J Czernuszewicz; Ryan Gessner; Ross Berbeco
Journal:  Ultrasound Med Biol       Date:  2019-11-04       Impact factor: 2.998

5.  Tri-modality cavitation mapping in shock wave lithotripsy.

Authors:  Mucong Li; Georgy Sankin; Tri Vu; Junjie Yao; Pei Zhong
Journal:  J Acoust Soc Am       Date:  2021-02       Impact factor: 1.840

6.  Implementation of a Novel 288-Element Dual-Frequency Array for Acoustic Angiography: In Vitro and In Vivo Characterization.

Authors:  Isabel G Newsome; Thomas M Kierski; Guofeng Pang; Jianhua Yin; Jing Yang; Emmanuel Cherin; F Stuart Foster; Claudia A Carnevale; Christine E M Demore; Paul A Dayton
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2021-07-26       Impact factor: 3.267

Review 7.  Preclinical Applications of Multi-Platform Imaging in Animal Models of Cancer.

Authors:  Natalie J Serkova; Kristine Glunde; Chad R Haney; Mohammed Farhoud; Alexandra De Lille; Elizabeth F Redente; Dmitri Simberg; David C Westerly; Lynn Griffin; Ralph P Mason
Journal:  Cancer Res       Date:  2020-12-01       Impact factor: 13.312

8.  Vascular amounts and dispersion of caliber-classified vessels as key parameters to quantitate 3D micro-angioarchitectures in multiple myeloma experimental tumors.

Authors:  Marco Righi; Silvia Laura Locatelli; Carmelo Carlo-Stella; Marco Presta; Arianna Giacomini
Journal:  Sci Rep       Date:  2018-11-30       Impact factor: 4.379

Review 9.  Modeling clear cell renal cell carcinoma and therapeutic implications.

Authors:  Melissa M Wolf; W Kimryn Rathmell; Kathryn E Beckermann
Journal:  Oncogene       Date:  2020-03-02       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.